About G-protein coupled receptor 42
G-protein coupled receptor 42 (GPR42) is a protein
from Homo sapiens identified by UniProt accession
O15529, 346 residues long.
MolForge cross-references it against 0 known binders and
20 disease associations.
Target properties
| Protein name | G-protein coupled receptor 42 |
| UniProt accession | O15529 |
| Gene | GPR42 |
| Organism | Homo sapiens |
| Length | 346 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (20)
Diseases linked to this target (Open Targets).
- MODY · score 0.08
- hyperinsulinism due to INSR deficiency · score 0.07
- hyperinsulinism due to glucokinase deficiency · score 0.06
- hyperproinsulinemia · score 0.06
- exercise-induced hyperinsulinism · score 0.05
- diabetes mellitus, transient neonatal, 2 · score 0.05
- hyperinsulinemic hypoglycemia, familial, 4 · score 0.04
- hepatorenocardiac degenerative fibrosis · score 0.04
- hyperinsulinemic hypoglycemia, familial, 1 · score 0.04
- kidney disease · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15529-F1 | alphafold | PREDICTED | 87.04 | — |
Amino-acid sequence (346 residues)
MDTGPDQSYF SGNHWFVFSV YLLTFLVGLP LNLLALVVFV GKLRCRPVAV DVLLLNLTAS DLLLLLFLPF RMVEAANGMH WPLPFILCPL SGFIFFTTIY LTALFLAAVS IERFLSVAHP LWYKTRPRLG QAGLVSVACW LLASAHCSVV YVIEFSGDIS HSQGTNGTCY LEFRKDQLAI LLPVRLEMAV VLFVVPLIIT SYCYSRLVWI LGRGGSHRRQ RRVAGLVAAT LLNFLVCFGP YNVSHVVGYI CGESPVWRIY VTLLSTLNSC VDPFVYYFSS SGFQADFHEL LRRLCGLWGQ WQQESSMELK EQKGGEEQRA DRPAERKTSE HSQGCGTGGQ VACAEN
Explore G-protein coupled receptor 42 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets